search
Back to results

A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

Primary Purpose

Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
BT-001
Pembrolizumab [Keytruda]
Sponsored by
Transgene
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Metastatic Cancer focused on measuring Superficial tumors, Metastatic cancer, Intratumoral, Safety, Oncolytic virus, Vaccinia virus, Solid tumors, Melanoma, Merkel, Sarcoma, TNBC, NSCLC, Pembrolizumab, BT-001, TG6030, Phase 1

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Have at least 1 injectable measurable cutaneous, subcutaneous or nodal lesion (direct injection or through the use of ultrasound guidance) measuring between 25 and 50mm in longest diameter and whenever possible 1 distant non-injected measurable lesion.
  • Provision of a fresh tumor sample of the lesion that will be injected first and, whenever possible, from another lesion that is planned to be injected, at baseline and be willing to supply new tumor samples from a biopsy during treatment.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
  • Have adequate hematological, hepatic and renal functions.

For Phase I patients:

  • Have histologically confirmed, advanced/metastatic sarcoma (soft tissue and bone), Merkel cell carcinoma, melanoma, triple negative breast cancer or non-small cell lung cancer, with cutaneous or, palpable subcutaneous lesions or easily injectable lymph nodes.
  • Have failed and/or are intolerant to standard therapeutic options.

Exclusion Criteria:

  • Have had major surgery within 4 weeks of first study drug administration.
  • Have received prior treatment with a vaccinia oncolytic virus.
  • Known significant immunodeficiency due to underlying illness (e.g., HIV/AIDS) and/or immune-suppressive medication including systemic corticosteroids.
  • History of severe exfoliative skin conditions (e.g., eczema or atopic dermatitis) requiring systemic therapy for more than 4 weeks within 2 years prior to BT-001 initiation.
  • Uncontrolled intercurrent illness including but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/social circumstances that could limit compliance with study requirements.
  • Have had a Grade ≥ 3 auto-immune manifestations of previous ICIs (e.g., anti-PD-1, anti-PDL1, anti-CTLA-4, or another immune checkpoint targeting agent under investigation).
  • Active brain metastasis (stable and treated metastasis are accepted). E8. Known hypersensitivity to egg or to any excipients of BT-001.
  • Have had any positive test for hepatitis C virus (HCV) or hepatitis B virus (HBV) indicating acute or chronic infection.
  • Pregnant or a breastfeeding woman.
  • Have received or receiving any live vaccine during the period of 28 days before IMP(s) administration, during IMP's administrations and 28 days after the last IMP's administration.
  • History of myocarditis or congestive heart failure, uncontrolled infection, or myocardial infarction 6 months prior to clinical trial entry.
  • Interstitial lung disease that is symptomatic and may interfere with the detection or management of suspected drug-related pulmonary toxicity

For patients included in Phase I, Part B and IIa only:

• Patient with an active known or suspected auto-immune disease. Patient with type I diabetes or hypothyroidism only requiring hormone replacement are permitted to enroll.

Sites / Locations

  • Clinique Universitaire Saint-LucRecruiting
  • Institut BergoniéRecruiting
  • Centre Léon BérardRecruiting
  • Hôpital Saint-Louis AP-HPRecruiting
  • Institut Gustave RoussyRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Phase I, Part A - Dose escalation and safety of BT-001 alone

Phase I, Part B - Safety of BT-001 in combination with pembrolizumab

Phase IIa - Expansion cohorts of BT-001 in combination with pembrolizumab

Arm Description

Dose escalation with repeated administrations of BT-001 directly into tumor as a single agent, in patients with metastatic or advanced solid tumors.

Repeated administrations of BT-001 directly into tumor in combination with infusions of pembrolizumab in patients with metastatic or advanced soft tissue sarcoma (STS), Merkel cell carcinoma (MCC), melanoma, triple negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC)..

Repeated administrations of BT-001 directly into tumor in combination with infusions of pembrolizumab in several cohorts of patients with defined metastatic or advanced solid tumor conditions: soft tissue sarcoma, Merkel cell carcinoma, melanoma, triple negative breast cancer, non-small cell lung cancer.

Outcomes

Primary Outcome Measures

Phase I: Safety and tolerability (Adverse Event reported per NCI-CTCAE v5.0)
Incidence of Adverse Event reported per NCI-CTCAE v5.0, Dose limiting toxicity and Serious Adverse Events.
Phase I, Part A: Recommended dose for Part B (RDPB) definition
RDPB based on the safety data collected during the dose escalation phase (Phase I, Part A).
Phase IIa (except Soft Tissue Sarcoma cohort): Immune Overall Response Rate (iORR) by iRECIST
Percentage of patients whose best overall response is either a Complete Response or a Partial Response according to immune Response Evaluation Criteria In Solid Tumors (iRECIST) criteria over the the total number of evaluable patients. for injected and non-injected lesion(s)
Phase IIa (Soft Tissue Sarcoma cohort): Immune Disease Control Rate (iDCR) at 6 months by iRECIST
Percentage of patients whose best overall response is either a Complete Response, a Partial Response or Stable Disease according to immune Response Evaluation Criteria In Solid Tumors (iRECIST) criteria over the the total number of evaluable patients.

Secondary Outcome Measures

Phase IIa: Safety and tolerability (Adverse Event reported per NCI-CTCAE v5.0)
Incidence of Adverse Event reported per NCI-CTCAE v5.0, Dose limiting toxicity and Serious Adverse Events.
Disease Control Rate (DCR) and immune DCR by RECIST version 1.1 and iRECIST
Percentage of patients whose best overall response is either a Complete Response, a Partial Response or Stable Disease according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) criteria or immune RECIST over the total number of evaluable patients.
Progression Free Survival (PFS) and immune PFS duration by RECIST version 1.1 and iRECIST
Time from the first BT-001 administration to the date of first documented tumor progression according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) criteria or immune RECIST or death due to any cause, whichever occurs first over evaluable patients
Duration of overall Response (DoR) and immune DOR by RECIST version 1.1 and iRECIST
Time from the date of first documented response (CR or PR) to the date of first documented disease progression according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) criteria or immune RECIST or the date of death due to underlying cancer over the number of patients whose Best Overall Response is Complete Response or Partial Response.
Overall Survival (OS) duration
Time from first BT-001 administration to the date of death due to any cause over evalauable patients.

Full Information

First Posted
January 25, 2021
Last Updated
October 10, 2023
Sponsor
Transgene
Collaborators
BioInvent International AB, Merck Sharp & Dohme LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT04725331
Brief Title
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Official Title
A Phase I/IIa Study of Intra-tumoral BT-001 (TG6030) Administered Alone and in Combination With Pembrolizumab in Patients With Cutaneous or, Subcutaneous Lesions or Easily Injectable Lymph Nodes of Metastatic/Advanced Solid Tumors.
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 25, 2021 (Actual)
Primary Completion Date
April 30, 2025 (Anticipated)
Study Completion Date
April 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Transgene
Collaborators
BioInvent International AB, Merck Sharp & Dohme LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab.
Detailed Description
This study will include 3 parts: Phase I, Part A: Repeated intra-tumoral (IT) administrations of BT-001 as a single agent, in patients with metastatic/advanced solid tumors; dose-escalation will be employed. Phase I, Part B: Repeated IT administrations of BT-001 in combination with intravenous (IV) infusions of pembrolizumab in patients with metastatic/advanced soft tissue sarcoma (STS), Merkel cell carcinoma (MCC), melanoma, triple negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC).. Phase IIa: Repeated IT administrations of BT-001 in combination with IV infusions of pembrolizumab in several cohorts of patients with defined metastatic or advanced solid tumor conditions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Non Small Cell Lung Cancer
Keywords
Superficial tumors, Metastatic cancer, Intratumoral, Safety, Oncolytic virus, Vaccinia virus, Solid tumors, Melanoma, Merkel, Sarcoma, TNBC, NSCLC, Pembrolizumab, BT-001, TG6030, Phase 1

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
48 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Phase I, Part A - Dose escalation and safety of BT-001 alone
Arm Type
Experimental
Arm Description
Dose escalation with repeated administrations of BT-001 directly into tumor as a single agent, in patients with metastatic or advanced solid tumors.
Arm Title
Phase I, Part B - Safety of BT-001 in combination with pembrolizumab
Arm Type
Experimental
Arm Description
Repeated administrations of BT-001 directly into tumor in combination with infusions of pembrolizumab in patients with metastatic or advanced soft tissue sarcoma (STS), Merkel cell carcinoma (MCC), melanoma, triple negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC)..
Arm Title
Phase IIa - Expansion cohorts of BT-001 in combination with pembrolizumab
Arm Type
Experimental
Arm Description
Repeated administrations of BT-001 directly into tumor in combination with infusions of pembrolizumab in several cohorts of patients with defined metastatic or advanced solid tumor conditions: soft tissue sarcoma, Merkel cell carcinoma, melanoma, triple negative breast cancer, non-small cell lung cancer.
Intervention Type
Biological
Intervention Name(s)
BT-001
Intervention Description
Oncolytic Vaccinia virus containing genes encoding the 4-E03 human recombinant anti-hCTLA4 antibody and human GM-CSF administered at different dose [Phase I, Part A]; one dose lower and at Recommended Dose for Part B [Phase I, Part B] by intra-tumoral (IT) route.
Intervention Type
Drug
Intervention Name(s)
Pembrolizumab [Keytruda]
Intervention Description
Programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
Primary Outcome Measure Information:
Title
Phase I: Safety and tolerability (Adverse Event reported per NCI-CTCAE v5.0)
Description
Incidence of Adverse Event reported per NCI-CTCAE v5.0, Dose limiting toxicity and Serious Adverse Events.
Time Frame
Up to 5 years
Title
Phase I, Part A: Recommended dose for Part B (RDPB) definition
Description
RDPB based on the safety data collected during the dose escalation phase (Phase I, Part A).
Time Frame
Week 10-12
Title
Phase IIa (except Soft Tissue Sarcoma cohort): Immune Overall Response Rate (iORR) by iRECIST
Description
Percentage of patients whose best overall response is either a Complete Response or a Partial Response according to immune Response Evaluation Criteria In Solid Tumors (iRECIST) criteria over the the total number of evaluable patients. for injected and non-injected lesion(s)
Time Frame
Up to 2 years
Title
Phase IIa (Soft Tissue Sarcoma cohort): Immune Disease Control Rate (iDCR) at 6 months by iRECIST
Description
Percentage of patients whose best overall response is either a Complete Response, a Partial Response or Stable Disease according to immune Response Evaluation Criteria In Solid Tumors (iRECIST) criteria over the the total number of evaluable patients.
Time Frame
Up to 6 months
Secondary Outcome Measure Information:
Title
Phase IIa: Safety and tolerability (Adverse Event reported per NCI-CTCAE v5.0)
Description
Incidence of Adverse Event reported per NCI-CTCAE v5.0, Dose limiting toxicity and Serious Adverse Events.
Time Frame
Up to 5 years
Title
Disease Control Rate (DCR) and immune DCR by RECIST version 1.1 and iRECIST
Description
Percentage of patients whose best overall response is either a Complete Response, a Partial Response or Stable Disease according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) criteria or immune RECIST over the total number of evaluable patients.
Time Frame
4 months or 6 months
Title
Progression Free Survival (PFS) and immune PFS duration by RECIST version 1.1 and iRECIST
Description
Time from the first BT-001 administration to the date of first documented tumor progression according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) criteria or immune RECIST or death due to any cause, whichever occurs first over evaluable patients
Time Frame
Up to 2 years
Title
Duration of overall Response (DoR) and immune DOR by RECIST version 1.1 and iRECIST
Description
Time from the date of first documented response (CR or PR) to the date of first documented disease progression according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) criteria or immune RECIST or the date of death due to underlying cancer over the number of patients whose Best Overall Response is Complete Response or Partial Response.
Time Frame
Up to 2 years
Title
Overall Survival (OS) duration
Description
Time from first BT-001 administration to the date of death due to any cause over evalauable patients.
Time Frame
Up to 2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Have at least 1 injectable measurable cutaneous, subcutaneous or nodal lesion (direct injection or through the use of ultrasound guidance) not exceeding 50mm in longest diameter and whenever possible 1 distant non-injected measurable lesion. Provision of a fresh tumor sample of the lesion that will be injected first and, whenever possible, from another lesion that is planned to be injected, at baseline and be willing to supply new tumor samples from a biopsy during treatment. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. Have adequate hematological, hepatic and renal functions. Have histologically confirmed, advanced/metastatic sarcoma (soft tissue and bone), Merkel cell carcinoma, melanoma, triple negative breast cancer or non-small cell lung cancer, with cutaneous or, palpable subcutaneous lesions or easily injectable lymph nodes. Have failed and/or are intolerant to standard therapeutic options. Exclusion Criteria: Have had major surgery within 4 weeks of first study drug administration. Have received prior treatment with a vaccinia oncolytic virus. Have received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to the start of treatment. Have received prior radiotherapy within 2 weeks of start of study treatment or have had a history of radiation pneumonitis Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 28 days prior the first dose of study drugs Have a known additional malignancy that is progressing or has required active treatment within the past 3 years. Have an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Have a history of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease Have an active infection requiring systemic therapy Have a known history of HIV infection Is taking an anticoagulant medication that cannot be interrupted prior to IT injections Have had an allogenic tissue/solid organ transplant or allogenic stem cell or bone marrow transplantation History of severe exfoliative skin conditions (e.g., eczema or atopic dermatitis) requiring systemic therapy for more than 4 weeks within 2 years prior to BT-001 initiation. Have received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137), and was discontinued from that treatment due to a Grade 3 or higher immune-related Adverse Event (irAE). Have known active CNS metastases and/or carcinomatous meningitis. Have a known history of Hepatitis B (defined as HBsAg reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection.n. Woman of childbearing potential who has a positive serum pregnancy test (within 72 hours) prior to the start of treatment. Have received or receiving any live or live-attenuated vaccine within 30 days prior to the first dose of study intervention.. History of myocarditis or congestive heart failure, unstable angina, uncontrolled infection, or myocardial infarction 6 months prior to clinical trial entry. Interstitial lung disease that is symptomatic and may interfere with the detection or management of suspected drug-related pulmonary toxicity Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment Have severe hypersensitivity to the active substance or, to any of the excipients of (≥Grade 3) to pembrolizumab. and/or any of its excipients
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Transgene EU, Clinical Operations Department
Phone
+ 33.3.88.27.91.00
Email
clinicaltrials@transgene.fr
Facility Information:
Facility Name
Clinique Universitaire Saint-Luc
City
Brussels
ZIP/Postal Code
1200
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pr Baurain
Facility Name
Institut Bergonié
City
Bordeaux
ZIP/Postal Code
33000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pr Italiano
Facility Name
Centre Léon Bérard
City
Lyon
ZIP/Postal Code
69008
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr Cassier
Facility Name
Hôpital Saint-Louis AP-HP
City
Paris
ZIP/Postal Code
75010
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pr Lebbé
Facility Name
Institut Gustave Roussy
City
Villejuif
ZIP/Postal Code
94800
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr Champiat

12. IPD Sharing Statement

Learn more about this trial

A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

We'll reach out to this number within 24 hrs